GI Dynamics Suspends Shipments of CE Marked Product
New Data Presented at EASD Demonstrate Robust Cardiometabolic Health Effects of EndoBarrier® Therapy in Obese People With and Without Diabetes
GI Dynamics, Inc. Appoints Daniel J. Moore to the Company’s Board of Directors
EndoBarrier® is indicated to treat patients with type 2 diabetes and/or obesity for 12 months.
EndoBarrier® has received regulatory approval and is commercially available for use in select international markets.
EndoBarrier® is not approved for sale in the United States and is considered investigational.
CAUTION: INVESTIGATIONAL DEVICE, LIMITED BY FEDERAL (UNITED STATES) LAW TO INVESTIGATIONAL USE